Future directions of bone-targeted therapy for metastatic breast cancer.
Bone is the most common metastatic site for breast cancer, and bone metastases can cause pain as well as risk of pathological fractures. Emerging treatments for metastatic bone disease have arisen from advances in our understanding of the unique cellular and molecular mechanisms that contribute to bone metastasis. The interaction between tumor cells and the bone microenvironment results in a 'vicious cycle' that increases both bone destruction and tumor burden. The tumor secretes factors, such as parathyroid hormone-related peptide, that stimulate osteoclastogenesis. Similarly, the bone stroma produces growth factors, such as transforming growth factor β, that promote tumor growth in bone. Therapeutic targeting of these microenvironmental factors is under intensive investigation. Other attractive therapeutic targets include signaling molecules, such as receptor activator of nuclear factor κB ligand, Src kinase, and cathepsin K, all of which regulate osteoclast function, and chemokine receptor 4, which is involved in the homing of tumor cells to bone. In this Review, we describe the progress and future directions of novel bone-targeted therapies that may reduce or prevent destructive bone metastasis from breast cancer. Novel modalities for predicting and monitoring treatment response will also be described.
Onishi
Tomifumi
T
Christus Hospital-St Elizabeth, 2830 Calder Street, Beaumont, TX 77702, USA.
Hayashi
Naoki
N
Theriault
Richard L
RL
Hortobagyi
Gabriel N
GN
Ueno
Naoto T
NT
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology*; D056657:Cathepsin K; D002628:Chemoreceptor Cells; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008024:Ligands; D016328:NF-kappa B; D010281:Parathyroid Hormone; D053245:RANK Ligand / Q000627:therapeutic use*; D016212:Transforming Growth Factor beta; D000077211:Zoledronic Acid; D019061:src-Family Kinases
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D008024:Ligands; D016328:NF-kappa B; D010281:Parathyroid Hormone; D053245:RANK Ligand; D016212:Transforming Growth Factor beta; D000069448:Denosumab; D000077211:Zoledronic Acid; D019061:src-Family Kinases; D056657:Cathepsin K
Nature. 2003 May 15;423(6937):337-42
12748652
Cancer Cell. 2009 Jul 7;16(1):67-78
19573813
J Clin Oncol. 2004 Jul 15;22(14):2942-53
15254062
J Cell Biol. 1994 Dec;127(6 Pt 2):2021-36
7806579
N Engl J Med. 2004 Aug 19;351(8):781-91
15317891
Exp Cell Res. 1988 Apr;175(2):266-76
3360056
J Med Chem. 2005 Dec 1;48(24):7535-43
16302795
Br J Cancer. 2003 Dec 1;89(11):2031-7
14647134
J Clin Oncol. 2006 May 20;24(15):2261-7
16636340
Ann Oncol. 2010 Jan;21(1):33-9
19602564
Annu Rev Cell Dev Biol. 1997;13:513-609
9442882
J Clin Invest. 1993 Jun;91(6):2791-5
8514886
Clin Exp Metastasis. 1999 Feb;17(1):27-34
10390144
N Engl J Med. 2004 Apr 15;350(16):1655-64
15084698
Oncology. 2010;78(3-4):282-8
20530974
Mol Cancer Res. 2009 Apr;7(4):476-88
19372577
Acta Oncol. 2008;47(4):740-6
18465343
J Biol Chem. 2002 Jul 19;277(29):26217-24
12011070
Mol Cancer Ther. 2006 Dec;5(12):3023-31
17172405
J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78
18695136
J Cell Biol. 2001 Jan 8;152(1):181-95
11149930
Cancer Res. 2003 Aug 15;63(16):5028-33
12941830
J Pathol. 1998 Jan;184(1):53-7
9582527
J Clin Oncol. 2008 Oct 20;26(30):4875-82
18725648
Cell. 2003 Jun 13;113(6):685-700
12809600
N Engl J Med. 2006 Feb 23;354(8):860-3
16495400
Nat Genet. 2001 Oct;29(2):117-29
11586292
Microsc Res Tech. 2001 Feb 15;52(4):387-95
11170297
Cancer Res. 2007 Oct 15;67(20):9894-902
17942921
Br J Cancer. 2003 May 19;88(10):1631-40
12771933
J Clin Invest. 1999 Jan;103(2):197-206
9916131
N Engl J Med. 2005 Aug 25;353(8):793-802
16120859
J Bone Miner Res. 2010 May;25(5):937-47
19874198
Br J Cancer. 2010 Mar 30;102(7):1099-105
20234364
J Pathol. 1996 Dec;180(4):383-8
9014858
Oncol Rep. 2006 May;15(5):1351-7
16596210
N Engl J Med. 2009 Aug 20;361(8):756-65
19671655
Biochem Biophys Res Commun. 1994 Mar 30;199(3):1237-44
8147865
J Clin Oncol. 2007 Oct 1;25(28):4431-7
17785705
Cell Biochem Funct. 1991 Jan;9(1):55-62
2065436
Cancer Res. 2007 Feb 15;67(4):1580-8
17308097
Oncol Rep. 2009 Mar;21(3):761-7
19212637
Cell. 1998 Apr 17;93(2):165-76
9568710
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
2673568
Cancer Res. 2006 Jul 1;66(13):6714-21
16818646
Clin Cancer Res. 2006 Feb 15;12(4):1221-8
16489077
Science. 1999 Feb 5;283(5403):845-8
9933168
Ann Oncol. 2008 Dec;19(12):2007-11
18664560
Clin Cancer Res. 2009 May 15;15(10):3396-405
19451593
J Pharmacol Exp Ther. 2006 Jul;318(1):161-72
16627750
Nat Rev Cancer. 2004 Jul;4(7):540-50
15229479
Breast Cancer Res Treat. 2009 May;115(1):57-67
18493848
Clin Breast Cancer. 2009 May;9(2):77-85
19433387
Lancet. 2001 Feb 3;357(9253):336-41
11210994
Lancet. 2005 Feb 19-25;365(9460):671-9
15721472
J Pharmacol Exp Ther. 2002 Sep;302(3):1055-61
12183663
Clin Breast Cancer. 2009 Aug;9(3):173-7
19661041
J Surg Res. 2009 Aug;155(2):231-6
19482312
Clin Exp Metastasis. 2007;24(3):157-67
17394086
J Clin Oncol. 2005 Mar 1;23(7):1420-30
15735118
N Engl J Med. 1998 Aug 6;339(6):398-400
9691109
Cancer. 2008 Jul 1;113(1):193-201
18459173
N Engl J Med. 2009 Feb 12;360(7):679-91
19213681
Cancer Res. 2006 Feb 15;66(4):2250-6
16489028
Acta Oncol. 2004;43(7):650-6
15545185
Ann Oncol. 2010 Nov;21(11):2188-2194
20444845
Breast Cancer Res Treat. 2006 Jun;97(3):263-74
16333527
Clin Cancer Res. 2008 Oct 15;14(20):6690-6
18927312
Cell. 2008 Jul 25;134(2):215-30
18662538
Ann Oncol. 2009 Jun;20(6):1013-9
19237480
Arthritis Rheum. 2008 May;58(5):1299-309
18438830
Cell. 1991 Feb 22;64(4):693-702
1997203
J Biol Chem. 1998 Nov 27;273(48):32347-52
9822715
Cancer Treat Rev. 2001 Jun;27(3):165-76
11417967
Eur J Cancer. 1997 May;33(6):918-25
9291816
Cancer Gene Ther. 2009 Aug;16(8):620-4
19287371
J Am Acad Dermatol. 2008 Jul;59(1):125-9
18410981
Curr Pharm Des. 2002;8(23):2049-75
12171518
Clin Breast Cancer. 2005 Feb;5 Suppl(2):S46-53
15807924
Clin Cancer Res. 2008 Jul 15;14(14):4658-66
18628481
N Engl J Med. 1998 Aug 6;339(6):357-63
9691101
Med Oncol. 2008;25(3):346-9
18204821
Anticancer Drugs. 2005 Sep;16(8):845-54
16096432
J Cell Biol. 1992 Nov;119(4):1003-13
1385441
J Clin Oncol. 2002 Feb 1;20(3):850-6
11821470
Breast Cancer Res Treat. 2009 Jun;115(3):453-95
18841463
Br J Cancer. 2007 Jun 18;96(12):1796-801
17325699
Cancer Metastasis Rev. 2003 Dec;22(4):337-58
12884910
Clin Exp Metastasis. 2008;25(2):119-29
18064531
J Clin Oncol. 2003 Aug 1;21(15):2869-75
12885803
Cancer Cell. 2003 Jun;3(6):537-49
12842083
Cancer Sci. 2007 Jan;98(1):127-33
17129361
J Biol Chem. 1996 May 24;271(21):12511-6
8647859
Cancer Res. 2007 Mar 1;67(5):2226-38
17332353
Lancet Oncol. 2010 May;11(5):421-8
20362507
Expert Opin Investig Drugs. 2010 Jan;19(1):77-91
20001556
Biomarkers. 2008 Mar;13(2):217-36
18270872
Eur Radiol. 2009 Oct;19(10):2495-507
19468736
Nat Rev Cancer. 2002 Aug;2(8):584-93
12154351
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13909-14
16172383
J Cell Biol. 2000 Oct 16;151(2):311-20
11038178
J Bone Miner Res. 1999 Oct;14(10):1654-63
10491212
Cancer Res. 2003 Sep 15;63(18):5679-84
14522883
J Clin Invest. 1996 Oct 1;98(7):1544-9
8833902
Nature. 2001 Mar 1;410(6824):50-6
11242036
J Med Chem. 2004 Dec 30;47(27):6658-61
15615512
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474
16034900
Breast Cancer Res Treat. 2007 Nov;105(3):319-26
17268817
J Clin Oncol. 2009 Apr 1;27(10):1564-71
19237632
Breast Cancer Res. 2006;8(2):R13
16542503
Cancer Res. 2002 Nov 15;62(22):6538-44
12438248
Am J Clin Oncol. 2008 Dec;31(6):532-8
19060583
Oncogene. 2009 Feb 19;28(7):1005-15
19079339
Clin Cancer Res. 2002 Oct;8(10):3172-7
12374685
Mol Cancer Ther. 2008 May;7(5):1185-94
18483306
J Clin Invest. 1992 Oct;90(4):1622-7
1383278
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13453-8
9811821
Cell. 2008 Apr 4;133(1):66-77
18394990
N Engl J Med. 2009 Aug 20;361(8):745-55
19671656
J Bone Miner Res. 2000 Nov;15(11):2211-21
11092402
Lancet Oncol. 2010 Mar;11(3):275-80
20149736
Curr Med Chem. 2003 Jan;10(2):173-80
12570716